Chengdu Kanghong Pharmaceutical Group Co., Ltd. announced it received a Notice of Approval for Drug Clinical Trial from the NMPA for KHN707 tablets. KHN707 is a self-developed selective orexin 2 (OX2R) receptor antagonist. The drug has shown good safety and therapeutic effects in preclinical studies, with promising clinical application prospects.
Summary generated by AI · Always verify with source document
Securities Code: 002773 Securities Abbreviation: Kanghong Pharmaceutical Announcement No.: 2026-005
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Announcement on Receiving Notice of Approval for Drug Clinical Trial
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.